MAPT and tauopathy: We demonstrated that sorafenib can significantly ameliorate cognitive deficits and tau pathologies in PS19 tauopathy model mice through multiple mechanisms, including promoting the E3 ubiquitin ligase FBXW7 to facilitate the degradation of tau and phosphorylated tau.